Published in Neurology on July 01, 1998
Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology (2003) 1.83
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One (2010) 1.44
Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis (2007) 1.05
Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol (2009) 0.98
HIV-1-infected astrocytes and the microglial proteome. J Neuroimmune Pharmacol (2008) 0.92
Chronic-treated HIV: a neurologic disease. J Urban Health (2000) 0.78
HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions. Curr Drug Targets (2015) 0.78
HIV-associated neurocognitive disorders: perspective on management strategies. Drugs (2013) 0.77
Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls. Neurotherapeutics (2016) 0.75
Combined chronic blockade of hyper-active L-type calcium channels and NMDA receptors ameliorates HIV-1 associated hyper-excitability of mPFC pyramidal neurons. Neurobiol Dis (2016) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Gonadotropic activity of the pituitaries of vitamin E deficient rats. J Physiol (1936) 8.43
Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature (2001) 5.60
A study of the unsaponifiable fraction of wheat germ oil with special reference to vitamin E. Biochem J (1935) 5.42
Ecology. The value of nature and the nature of value. Science (2000) 5.32
The effects of response rate changes on the index of consumer sentiment. Public Opin Q (2000) 5.11
Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A (1995) 4.84
Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology (2011) 4.63
Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature (2001) 4.35
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med (1998) 4.09
Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron (1995) 4.07
Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. Am J Prev Med (2001) 3.97
Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol (1995) 3.78
(S)NO signals: translocation, regulation, and a consensus motif. Neuron (1997) 3.67
HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology (2001) 3.55
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science (1990) 3.41
HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 3.17
EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol (2005) 3.17
Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology (2007) 3.14
Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med (1998) 2.99
Further observations on the constituents of the unsaponifiable fraction of wheat germ oil with particular reference to vitamin E. Biochem J (1935) 2.95
Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A (1998) 2.89
Leverage-saliency theory of survey participation: description and an illustration. Public Opin Q (2000) 2.80
Experiments with incentives in telephone surveys. Public Opin Q (2000) 2.60
Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet (1991) 2.60
Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature (1998) 2.59
The search for effective and efficient ambulatory teaching methods through the literature. Pediatrics (2000) 2.57
HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ (2005) 2.54
Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron (1992) 2.54
Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52
Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology (1999) 2.52
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology (1999) 2.49
Clinical-neuropathologic correlation in HIV-associated dementia. Neurology (1993) 2.47
Defining and evaluating quality for ambulatory care educational programs. Acad Med (1997) 2.43
hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors. Mol Cell Biol (1993) 2.41
Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A (1999) 2.40
Mortality and mental health: evidence from the Midtown Manhattan Restudy. Soc Sci Med (1977) 2.36
Routine operation of an Elliott 903 computer in a clinical chemistry laboratory. J Clin Pathol (1973) 2.35
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci (1992) 2.25
Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci (2000) 2.24
Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol (1996) 2.22
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
Neuropsychological performance in HIV-1-infected homosexual men: The Multicenter AIDS Cohort Study (MACS) Neurology (1990) 2.17
Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology (2002) 2.17
Inequalities in health in the city of Bristol: a preliminary review of statistical evidence. Int J Health Serv (1985) 2.17
Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology (1997) 2.15
Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci U S A (2006) 2.15
Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med (1995) 2.11
Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world. S Afr Med J (2001) 2.10
Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol (1993) 2.09
MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc Natl Acad Sci U S A (1993) 2.07
HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology (2006) 2.06
Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol (1998) 2.05
Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol (1987) 2.05
State scholarship, loan forgiveness, and related programs: the unheralded safety net. JAMA (2000) 2.03
Long-term health effects of harness-mounted radio transmitters in red kites (Milvus milvus) in England. Vet Rec (2011) 2.03
Effects of vitamin E deficiency on the thyroid gland of the rat. J Physiol (1936) 1.96
Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology (1995) 1.95
Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology (1988) 1.94
Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology (1999) 1.93
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology (2007) 1.90
Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology (1994) 1.88
Major incident plans. Anaesthesia (1992) 1.87
The neuropathogenesis of HIV-1 infection. J Leukoc Biol (1994) 1.83
Mitochondrial fission is an upstream and required event for bax foci formation in response to nitric oxide in cortical neurons. Cell Death Differ (2006) 1.77
Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science (1996) 1.76
Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors. J Neurosci (2001) 1.75
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol (2009) 1.75
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74
Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res (1997) 1.74
Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol (1993) 1.73
Blood loss after total knee replacement: effects of computer-assisted surgery. J Bone Joint Surg Br (2005) 1.72
Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology (1999) 1.71
Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci (1995) 1.70
Cerebellar degeneration associated with human immunodeficiency virus infection. Neurology (1998) 1.69
Biomarkers of HIV-1 CNS infection and injury. Neurology (2007) 1.69
Pediatric coma scale. Lancet (1982) 1.69
Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology (1993) 1.68
Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol (1997) 1.66
Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia. Neurology (2004) 1.66
Selective modulation of NMDA responses by reduction and oxidation. Neuron (1989) 1.64
Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol (1996) 1.64
Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor. Neuron (1999) 1.62
Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology (2007) 1.62
Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study. Percept Mot Skills (1991) 1.62
Phrenic nerve dysfunction after cardiac operations: electrophysiologic evaluation of risk factors. Chest (1998) 1.61
Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol (2012) 1.60
New perspectives on glaucoma. JAMA (1999) 1.60
Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg (2001) 1.59
Cytokine expression of macrophages in HIV-1-associated vacuolar myelopathy. Neurology (1993) 1.59
Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. Trends Neurosci (1989) 1.59
Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol (2000) 1.58